CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions

Patil, T., Lin, J. J., Cheema, P. K., Carrizosa, D. R., Burkard, M. E., Elamin, Y. Y., … Liu, S. V. (2025). CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions. JCO Precision Oncology, (9). https://doi.org/10.1200/po-25-00221